PLYMOUTH MEETING, Pa., Nov. 18, 2025
PLYMOUTH MEETING, Pa., Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences:
Piper Sandler 37th Annual Healthcare Conference (New York, NY)
Date: Tuesday, December 2
Time: 8:30-8:55 AM ET
Format: Fireside Chat
Webcast: https://bit.ly/44af19l (live webcast and replay available for 90 days after the event)
Oppenheimer Movers in Rare Disease Summit (New York, NY)
Date: Thursday, December 11
Time: 12:05-12:25 PM ET
Format: Panel - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts
Members of INOVIO's management team will also be conducting one-on-one meetings with investors during these conferences.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-december-investor-conferences-302618252.html
SOURCE INOVIO Pharmaceuticals, Inc.

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.